An assessment of extended pembrolizumab dosing in advanced non-small-cell lung cancer in the COVID-19 pandemic.

Publication date: Jul 11, 2023

Background: There are limited clinical data comparing extended dosing (ED) versus standard dosing (SD) of pembrolizumab for metastatic non-small-cell lung cancer. Methods: This retrospective study included patients with metastatic non-small-cell lung cancer and PD-L1 tumor proportion score ≥50% treated with one or more cycles of single-agent pembrolizumab with SD or ED from January 2018 to December 2020. Results: A higher proportion of patients were alive in the ED group (vs SD) at 6 months (94 vs 51%), 12 months (94 vs 33%) and data cutoff (94 vs 26%) (p

Concepts Keywords
6months alternative dosing
Cancer immunotherapy
December non-small-cell lung cancer
Pandemic outcomes
Pembrolizumab pembrolizumab


Type Source Name
drug DRUGBANK Pembrolizumab
disease IDO cell
disease MESH lung cancer
disease MESH COVID-19 pandemic
disease MESH tumor

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *